Global Blau syndrome market is projected to register a healthy CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Global Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Brazil, Argentina and Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and Rest of Middle East and Africa) - Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of global Blau syndrome market are:

- Emergence of drugs used to treat symptoms associated with Blau syndrome
- Advancement in health care industry
Market Players:

The key market players for global Blau syndrome market are listed below:

- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Amgen Inc.
- Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
- Mylan N.V.
- Hikma Pharmaceuticals PLC
- Teva Pharmaceutical U.S.A Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
- Fulgent Genetics Inc.
- Invitae Corporation
- Swedish Orphan Biovitrum AB
- Alkem Labs
- Accord Healthcare
- F. Hoffmann-La Roche Ltd
- Zydus Pharmaceuticals (USA) Inc. (a subsidiary of Zydus cadila)
- Amneal Pharmaceuticals LLC
- Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.)
- Centogene AG
- Oncodesign